NeoGenomics to Participate in Upcoming Investor Conferences

Business Wire

02-24

FT. MYERS, Fla., February 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:

TD Cowen 45^th Annual Health Care Conference in Boston, MA
Fireside chat on Tuesday, March 4at 1:50 p.m. ET, accessible here
Leerink Partners Global Healthcare Conference in Miami, FL
Fireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here
Barclays 27^th Annual Global Healthcare Conference in Miami, FL
Fireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here

Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250224577544/en/

Contacts

Investor Contact
Kendra Sweeney
Kendra.sweeney@neogenomics.com

Media Contact
Andrea Sampson
asampson@sampsonprgroup.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2513728049"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513728049\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2513728049?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 20:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2513728049","market":"us","top_or_hot":-1,"title":"NeoGenomics to Participate in Upcoming Investor Conferences","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"984\" src=\"https://s1.yimg.com/uu/api/res/1.2/p9lhVg1YjpcncjL920i3qA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/df53902b643a4a571e72b3108d6bec91\" title=\"\" width=\"2390\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>FT. MYERS, Fla., February 24, 2025</b>--(BUSINESS WIRE)--<b><a href=\"https://laohu8.com/S/NEO\">NeoGenomics</a>, Inc. (\"NeoGenomics\" or the \"Company\") (NASDAQ:NEO),</b> a leading oncology testing services company, today announced the Company will participate in the following investor conferences:</p>\n<ul>\n<li>TD Cowen 45<sup>th</sup> Annual Health Care Conference in Boston, MA<br/>Fireside chat on Tuesday, March 4<sup> </sup>at 1:50 p.m. ET, accessible here<br/></li>\n<li>Leerink Partners Global Healthcare Conference in Miami, FL<br/>Fireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here<br/></li>\n<li>Barclays 27<sup>th</sup> Annual Global Healthcare Conference in Miami, FL<br/>Fireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here<br/></li>\n</ul>\n<p>Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.</p>\n<p><b>About NeoGenomics</b></p>\n<p>NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250224577544/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Investor Contact </b><br/>Kendra Sweeney<br/>Kendra.sweeney@neogenomics.com<br/><br/></p>\n<p><b>Media Contact </b><br/>Andrea Sampson<br/>asampson@sampsonprgroup.com<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeoGenomics to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeoGenomics to Participate in Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-24 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/neogenomics-participate-upcoming-investor-conferences-120500735.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FT. MYERS, Fla., February 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (\"NeoGenomics\" or the \"Company\") (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will ...</p>\n\n<a href=\"https://finance.yahoo.com/news/neogenomics-participate-upcoming-investor-conferences-120500735.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0012050646.USD","symbol_name":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","start_time":0,"source_url":"https://finance.yahoo.com/news/neogenomics-participate-upcoming-investor-conferences-120500735.html","article_id":"2513728049","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513728049","pubTimestamp":1740398700,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"FT. MYERS, Fla., February 24, 2025----NeoGenomics, Inc.  , a leading oncology testing services company, today announced the Company will participate in the following investor conferences:. TD Cowen 45th Annual Health Care Conference in Boston, MAFireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here. Leerink Partners Global Healthcare Conference in Miami, FLFireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here. Barclays 27th Annual Global Healthcare Conference in Miami, FLFireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in F","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4196":"保健护理服务","NEO":"NeoGenomics","BK4121":"生命科学工具和服务","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC"},"translate_title":"NeoGenomics将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEO":1},"content_text":"FT. MYERS, Fla., February 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (\"NeoGenomics\" or the \"Company\") (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:\n\nTD Cowen 45th Annual Health Care Conference in Boston, MAFireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here\nLeerink Partners Global Healthcare Conference in Miami, FLFireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here\nBarclays 27th Annual Global Healthcare Conference in Miami, FLFireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here\n\nLive and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.\nAbout NeoGenomics\nNeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250224577544/en/\nContacts\nInvestor Contact Kendra SweeneyKendra.sweeney@neogenomics.com\nMedia Contact Andrea Sampsonasampson@sampsonprgroup.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}